Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.…
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
Vogenx (NASDAQ: VOGX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 11.87 USD on 20 November 2026. Its 52-week range is 11.51 USD to 38.41 USD: the price is 69.1% below the high and 3.2% above the low.
Its market capitalisation is 176.33M USD.
Vogenx reports return on equity of 157.3% and an operating margin of 0.0%.
Its debt exceeds its cash by 674.68K USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 12 March 2027.